Millipore has acquired Oxford, UK-based BioAnaLab. The transaction enables Millipore to expand its biopharmaceutical services business into Europe and strengthen its position in the biopharmaceutical industry.
The services offered by BioAnaLab include: assay transfer/development, validation & sample analysis, pharmacokinetics/ toxicokinetics, immunogenicity, biological potency, and vaccine services. Millipore is likely to bring expertise in biomarker analytical services to strengthen BioAnaLab’s current offering in that area.
Jonathan DiVincenzo, president of Bioscience division at Millipore, said: “As an increasing number of biologics enter the pipeline, companies are leveraging Millipore’s ligand binding assay expertise to help them evaluate the efficacy of these drugs and achieve regulatory compliance.
“Our acquisition of BioAnaLab will allow us to build on our reputation as a trusted outsource partner in North America by establishing a presence in the fast-growing European biotech market. BioAnaLab will add cGMP support testing capabilities to our portfolio, a solid customer base, and a team of highly talented services professionals with expertise in emerging scientific disciplines,” he added.